Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 12/20 | 0.61 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.59 |
| ▸ | HTT | P42858 | 1/20 | 0.59 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | MAOA | P21397 | 2/20 | 0.48 |
| ▸ | GLA | P06280 | 1/20 | 0.46 |
| ▸ | USP2 | O75604 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.42 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29933483 | 0.88 | KDM4E (0.52) | MAOBKDM4EHTTPTPN1KMT2A | |
| SCHEMBL6614160 | 0.88 | KDM4E (0.52) | MAOBKDM4EHTTPTPN1KMT2A | |
| SCHEMBL31195255 | 0.87 | MAOB (0.61) | MAOBKDM4EHTTPTPN1KMT2A | |
| SCHEMBL11268699 | 0.86 | PTPN1 (0.55) | MAOBKDM4EHTTPTPN1KMT2A | |
| SCHEMBL6720446 | 0.84 | MAOB (0.51) | MAOBKDM4EHTTPTPN1KMT2A | |
| Hydrochloric Acid SCHEMBL11271928 | 0.84 | PTPN1 (0.54) | MAOBKDM4EHTTPTPN1KMT2A | |
| SCHEMBL11268698 | 0.83 | KDM4E (0.48) | MAOBKDM4EHTTPTPN1KMT2A | |
| SCHEMBL3344909 | 0.81 | MAOB (0.61) | MAOBKDM4EHTTPTPN1KMT2A | |
| SCHEMBL11513004 | 0.81 | MAOB (0.67) | MAOBKDM4EHTTKMT2AMEN1 | |
| SCHEMBL31723115 | 0.81 | MAOB (0.61) | MAOBKDM4EHTTPTPN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118924749-A | Preparation method of chromone amide compound for Alzheimer disease drug | 广西民族大学 | 2024-11-12 | — | — | CN | claimed |
| US-12329755-B2 | Bromodomain inhibitors to target therapy-resistant cancer | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) | 2025-06-17 | — | — | US | disclosed |
| CN-118924749-A | Preparation method of chromone amide compound for Alzheimer disease drug | 广西民族大学 | 2024-11-12 | — | — | CN | disclosed |
| CN-118924749-A | Preparation method of chromone amide compound for Alzheimer disease drug | 广西民族大学 | 2024-11-12 | — | — | CN | disclosed |
| US-20220296592-A1 | BROMODOMAIN INHIBITORS TO TARGET THERAPY-RESISTANT CANCER | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION | 2022-09-22 | — | — | US | disclosed |
| US-20220296592-A1 | BROMODOMAIN INHIBITORS TO TARGET THERAPY-RESISTANT CANCER | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION | 2022-09-22 | — | — | US | disclosed |
| WO-2021041801-A1 | BROMODOMAIN INHIBITORS TO TARGET THERAPY-RESISTANT CANCER | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) | 2021-03-04 | — | — | WO | disclosed |
| US-20160030443-A1 | METHODS AND COMPOSITIONS FOR MODULATING REGULATORY T CELL FUNCTION | WANG RONGFU (US) | 2016-02-04 | — | — | US | disclosed |
| US-20160030443-A1 | METHODS AND COMPOSITIONS FOR MODULATING REGULATORY T CELL FUNCTION | WANG RONGFU (US) | 2016-02-04 | — | — | US | disclosed |
| US-20160030443-A1 | METHODS AND COMPOSITIONS FOR MODULATING REGULATORY T CELL FUNCTION | WANG RONGFU (US) | 2016-02-04 | — | — | US | disclosed |
| US-20080300298-A1 | Honokiol Derivates For the Treatment of Proliferative Disorders | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2008-12-04 | — | — | US | disclosed |
| US-20080300298-A1 | Honokiol Derivates For the Treatment of Proliferative Disorders | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2008-12-04 | — | — | US | disclosed |
| US-20080300298-A1 | Honokiol Derivates For the Treatment of Proliferative Disorders | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2008-12-04 | — | — | US | disclosed |
| US-4159268-A | ANTIBIOTICS, MICROBIOCIDES | AMERICAN CYANAMID COMPANY (US) | 1979-06-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220296592-A1 | BROMODOMAIN INHIBITORS TO TARGET THERAPY-RESISTANT CANCER | BRD1, SMARCE1, SMARCA1 | MAOB 4607/4885KDM4E 361/4885HTT 3344/4885 |
| US-12329755-B2 | Bromodomain inhibitors to target therapy-resistant cancer | BRD1, SMARCE1, SMARCA1 | MAOB 4607/4885KDM4E 361/4885HTT 3344/4885 |
| US-20080300298-A1 | Honokiol Derivates For the Treatment of Proliferative Disorders | CCNK, CDK3, CCNO | MAOB 3989/4885KDM4E 2859/4885HTT 1332/4885 |
| US-20160030443-A1 | METHODS AND COMPOSITIONS FOR MODULATING REGULATORY T CELL FUNCTION | IRAK4, TLR8, TLR4 | MAOB 2828/4885KDM4E 665/4885HTT 4093/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.